We are live on
!
Find out more
ProShare Advisors Portfolio holdings
AUM
$67.5B
1-Year Est. Return
28.09%
This Quarter
Est. Return
-12.35%
1 Year Est. Return
+28.09%
3 Year Est. Return
+88.43%
5 Year Est. Return
+118.21%
10 Year Est. Return
+464.8%
AUM
$14.3B
AUM Growth
-$444M
(-3%)
Cap. Flow
+$1.68B
Cap. Flow
% of AUM
11.73%
Top 10 Holdings %
Top 10 Hldgs %
21.62%
Holding
1,821
New
56
Increased
555
Reduced
957
Closed
250
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$101M |
| 2 |
Amazon
AMZN
|
+$99.5M |
| 3 |
Microsoft
MSFT
|
+$95.8M |
| 4 |
Linde
LIN
|
+$84.2M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$40.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PX
Praxair Inc
PX
|
+$77.4M |
| 2 |
ESRX
Express Scripts Holding Company
ESRX
|
+$35.2M |
| 3 |
McCormick & Company Non-Voting
MKC
|
+$14.7M |
| 4 |
CA
CA, Inc.
CA
|
+$13.2M |
| 5 |
Clorox
CLX
|
+$12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.27% |
| 2 | Healthcare | 13.08% |
| 3 | Financials | 12.21% |
| 4 | Consumer Discretionary | 10.94% |
| 5 | Consumer Staples | 10.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1426
MediciNova
MNOV
$65M
| $150K | ﹤0.01% |
+18,396
| New | +$184K |
|
|
ADAP
1427
DELISTED
Adaptimmune Therapeutics
ADAP
| $149K | ﹤0.01% |
25,944
-1,146
| -4% | -$8.46K |
|
1428
Element Solutions
ESI
$9.12B
| $148K | ﹤0.01% |
14,279
-2,250
| -14% | -$24.8K |
|
1429
Mueller Water Products
MWA
$3.92B
| $148K | ﹤0.01% |
16,300
-2,628
| -14% | -$27.6K |
|
|
BRKL
1430
DELISTED
Brookline Bancorp
BRKL
| $146K | ﹤0.01% |
10,588
-1,112
| -10% | -$16.8K |
|
|
FPRX
1431
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $145K | ﹤0.01% |
15,548
-3,064
| -16% | -$36.5K |
|
1432
Corbus Pharmaceuticals
CRBP
$170M
| $144K | ﹤0.01% |
822
-159
| -16% | -$31.7K |
|
|
INN
1433
Summit Hotel Properties
INN
$761M
| $135K | ﹤0.01% |
13,830
-1,470
| -10% | -$16.7K |
|
|
ARQL
1434
DELISTED
Arqule Inc
ARQL
| $134K | ﹤0.01% |
48,368
+35,102
| +265% | +$134K |
|
1435
Antero Resources
AR
$10.9B
| $132K | ﹤0.01% |
14,010
+2,875
| +26% | +$42.5K |
|
|
PR
1436
Permian Resources
PR
$17.9B
| $131K | ﹤0.01% |
11,855
+2,481
| +26% | +$42.6K |
|
|
CRZO
1437
DELISTED
Carrizo Oil & Gas Inc
CRZO
| $131K | ﹤0.01% |
11,605
-1,244
| -10% | -$22.1K |
|
|
PETX
1438
DELISTED
Aratana Therapeutics, Inc.
PETX
| $131K | ﹤0.01% |
21,389
-3,612
| -14% | -$22K |
|
1439
Aclaris Therapeutics
ACRS
$730M
| $130K | ﹤0.01% |
17,607
+1,704
| +11% | +$17.6K |
|
1440
Builders FirstSource
BLDR
$7.84B
| $130K | ﹤0.01% |
11,919
-1,909
| -14% | -$24K |
|
|
GCI
1441
DELISTED
Gannett Co., Inc
GCI
| $130K | ﹤0.01% |
15,239
-1,614
| -10% | -$15.8K |
|
|
DERM
1442
DELISTED
Dermira, Inc.
DERM
| $129K | ﹤0.01% |
17,931
-3,469
| -16% | -$38K |
|
|
CNCE
1443
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $128K | ﹤0.01% |
10,171
-1,982
| -16% | -$27.4K |
|
1444
Archrock
AROC
$6.33B
| $127K | ﹤0.01% |
16,999
-1,831
| -10% | -$18.6K |
|
|
RPT
1445
DELISTED
RPT Realty Common Shares of Beneficial Interest (MD)
RPT
| $127K | ﹤0.01% |
10,611
-1,122
| -10% | -$14.8K |
|
1446
Newmark Group
NMRK
$2.73B
| $126K | ﹤0.01% |
+15,750
| New | +$149K |
|
1447
Voyager Therapeutics
VYGR
$187M
| $125K | ﹤0.01% |
13,276
-2,576
| -16% | -$33.1K |
|
|
CLDR
1448
DELISTED
Cloudera, Inc.
CLDR
| $124K | ﹤0.01% |
11,183
-1,464
| -12% | -$19.5K |
|
|
TBIO
1449
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $123K | ﹤0.01% |
+16,335
| New | +$120K |
|
|
WPG
1450
DELISTED
Washington Prime Group Inc.
WPG
| $123K | ﹤0.01% |
2,802
-298
| -10% | -$16.7K |
|
Similar funds
ProShare Advisors's Q4 2018 Portfolio in Review
As of Q4 2018, ProShare Advisors held 1,821 positions worth $14.3B, down 3% from $14.7B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
ProShare Advisors deployed $1.68B of net new capital in Q4 2018, opening 56 new positions and adding to 555 existing holdings. Its largest new stake was Linde: 532,831 shares worth $83.1M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, down from 19% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was McCormick & Company Non-Voting, an estimated $14.7M trimmed.
- ProShare Advisors's largest Q4 2018 buy was Linde: 532,831 shares worth $83.1M.
- ProShare Advisors added most to Apple in Q4 2018, an estimated $101M increase.
- ProShare Advisors's biggest Q4 2018 reduction was McCormick & Company Non-Voting, cutting an estimated $14.7M.
- ProShare Advisors fully exited Praxair Inc in Q4 2018, selling an estimated $77.4M.
- ProShare Advisors's ten largest holdings make up 22% of its $14.3B portfolio in Q4 2018.
- ProShare Advisors opened 56 new positions and closed 250 in Q4 2018.
- ProShare Advisors's portfolio value fell 3% quarter-over-quarter to $14.3B.
Based on ProShare Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.